Literature DB >> 1469426

Electron microscopic features of skin in neurometabolic disorders.

C Ceuterick1, J J Martin.   

Abstract

Skin biopsy may contribute to the clinical diagnosis of neurometabolic disorders. It is an easy and much less traumatic procedure than brain, rectal, peripheral nerve and skeletal muscle biopsies. The method is informative and not too time-consuming for an experienced examiner. Differential diagnosis is possible in most storage disorders since the ultrastructure of the storage is virtually typical in lysosomal and in nonlysosomal diseases. The storage has a particular distribution with characteristic ultrastructural patterns in the various cell types. Skin biopsy plays a major diagnostic role when clinical features are atypical for a storage disorder, to discover new phenotypic variants of known enzymatic deficiencies or when the biochemical defect has not yet been determined. It can be used as a screening procedure to orientate the investigations, to suggest specific biochemical assays on cultured fibroblasts or other tissues or body fluids. It can be applied to detect "presymptomatic" patients in affected families. Other disorders of the nervous system should be investigated in the future to ascertain whether skin biopsies could possibly be used for diagnostic purposes. Thorough knowledge of the morphological features of these disorders may also improve the understanding of their pathogenesis, shed some light on the underlying basic defects and control the results of therapy.

Entities:  

Mesh:

Year:  1992        PMID: 1469426     DOI: 10.1016/0022-510x(92)90126-6

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  3 in total

1.  Nerve biopsy findings in Niemann-Pick type II (NPC)

Authors:  C Ceuterick; J J Martin
Journal:  Acta Neuropathol       Date:  1994       Impact factor: 17.088

2.  Juvenile-onset motor neuron disease caused by novel mutations in β-hexosaminidase.

Authors:  Tyler Mark Pierson; Paola A Torres; Bei-Jin Zeng; Allan M Glanzman; David Adams; Richard S Finkel; Don J Mahuran; Gregory M Pastores; Gihan I Tennekoon; Edwin H Kolodny
Journal:  Mol Genet Metab       Date:  2012-11-02       Impact factor: 4.797

3.  Fabry disease in a patient with Turner syndrome.

Authors:  R Brouns; F Eyskens; K De Boeck; C Ceuterick-de Groote; M Van den Broeck; C Van Broeckhoven; P P De Deyn
Journal:  J Inherit Metab Dis       Date:  2009-04-05       Impact factor: 4.982

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.